Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery

An emerging cause of morbidity and mortality

Bahaaldin Alsoufi, Lynn Boshkov, Aileen Kirby, Laura Ibsen, Nancy Dower, Irving Shen, Ross Ungerleider

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Unfractionated heparin (UFH) is immunogenic, and heparin-dependent antibodies can be demonstrated 5 to 10 days postoperatively in 25% to 50% of adult postcardiac surgery patients. In a minority of these cases (1% to 3% if UFH is continued longer than 1 week) these antibodies strongly activate platelets, causing thrombocytopenia and massive thrombin generation (HIT syndrome). HIT is an intensely procoagulant disorder, and in adult cardiac surgery patients carries both significant thrombotic morbidity (38% to 81%) and mortality (28%). Despite the ubiquitous use of UFH in pediatric intensive care units, and the repeated and sustained exposures to UFH in neonates and young children with congenital heart disease, HIT has been infrequently recognized and reported in this patient population. However, emerging experience at our institution and elsewhere suggests that HIT is significantly under-recognized in pediatric congenital heart disease patients, and may in fact have an incidence and associated thrombotic morbidity and mortality in this patient group comparable to that seen in adult cardiac surgery patients. This article will review HIT in pediatric patients with congenital heart disease and emphasize the special challenges posed in clinical recognition, laboratory diagnosis, and treatment of HIT in this patient group. We will also outline our experience with the off-label use of the direct thrombin inhibitor, argatroban, in pediatric patients with HIT.

Original languageEnglish (US)
Pages (from-to)155-171
Number of pages17
JournalPediatric Cardiac Surgery Annual
Volume7
StatePublished - 2004

Fingerprint

Thrombocytopenia
Thoracic Surgery
Heparin
Pediatrics
Morbidity
Mortality
Heart Diseases
Off-Label Use
Pediatric Intensive Care Units
Antithrombins
Antibodies
Clinical Laboratory Techniques
Thrombin
Blood Platelets
Newborn Infant

Keywords

  • Congenital heart disease
  • Heparin-induced thrombocytopenia
  • Pediatric cardiology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery : An emerging cause of morbidity and mortality. / Alsoufi, Bahaaldin; Boshkov, Lynn; Kirby, Aileen; Ibsen, Laura; Dower, Nancy; Shen, Irving; Ungerleider, Ross.

In: Pediatric Cardiac Surgery Annual, Vol. 7, 2004, p. 155-171.

Research output: Contribution to journalArticle

@article{27568e804b3e4304a67250cd669b696f,
title = "Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: An emerging cause of morbidity and mortality",
abstract = "Unfractionated heparin (UFH) is immunogenic, and heparin-dependent antibodies can be demonstrated 5 to 10 days postoperatively in 25{\%} to 50{\%} of adult postcardiac surgery patients. In a minority of these cases (1{\%} to 3{\%} if UFH is continued longer than 1 week) these antibodies strongly activate platelets, causing thrombocytopenia and massive thrombin generation (HIT syndrome). HIT is an intensely procoagulant disorder, and in adult cardiac surgery patients carries both significant thrombotic morbidity (38{\%} to 81{\%}) and mortality (28{\%}). Despite the ubiquitous use of UFH in pediatric intensive care units, and the repeated and sustained exposures to UFH in neonates and young children with congenital heart disease, HIT has been infrequently recognized and reported in this patient population. However, emerging experience at our institution and elsewhere suggests that HIT is significantly under-recognized in pediatric congenital heart disease patients, and may in fact have an incidence and associated thrombotic morbidity and mortality in this patient group comparable to that seen in adult cardiac surgery patients. This article will review HIT in pediatric patients with congenital heart disease and emphasize the special challenges posed in clinical recognition, laboratory diagnosis, and treatment of HIT in this patient group. We will also outline our experience with the off-label use of the direct thrombin inhibitor, argatroban, in pediatric patients with HIT.",
keywords = "Congenital heart disease, Heparin-induced thrombocytopenia, Pediatric cardiology",
author = "Bahaaldin Alsoufi and Lynn Boshkov and Aileen Kirby and Laura Ibsen and Nancy Dower and Irving Shen and Ross Ungerleider",
year = "2004",
language = "English (US)",
volume = "7",
pages = "155--171",
journal = "Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual",
issn = "1092-9126",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery

T2 - An emerging cause of morbidity and mortality

AU - Alsoufi, Bahaaldin

AU - Boshkov, Lynn

AU - Kirby, Aileen

AU - Ibsen, Laura

AU - Dower, Nancy

AU - Shen, Irving

AU - Ungerleider, Ross

PY - 2004

Y1 - 2004

N2 - Unfractionated heparin (UFH) is immunogenic, and heparin-dependent antibodies can be demonstrated 5 to 10 days postoperatively in 25% to 50% of adult postcardiac surgery patients. In a minority of these cases (1% to 3% if UFH is continued longer than 1 week) these antibodies strongly activate platelets, causing thrombocytopenia and massive thrombin generation (HIT syndrome). HIT is an intensely procoagulant disorder, and in adult cardiac surgery patients carries both significant thrombotic morbidity (38% to 81%) and mortality (28%). Despite the ubiquitous use of UFH in pediatric intensive care units, and the repeated and sustained exposures to UFH in neonates and young children with congenital heart disease, HIT has been infrequently recognized and reported in this patient population. However, emerging experience at our institution and elsewhere suggests that HIT is significantly under-recognized in pediatric congenital heart disease patients, and may in fact have an incidence and associated thrombotic morbidity and mortality in this patient group comparable to that seen in adult cardiac surgery patients. This article will review HIT in pediatric patients with congenital heart disease and emphasize the special challenges posed in clinical recognition, laboratory diagnosis, and treatment of HIT in this patient group. We will also outline our experience with the off-label use of the direct thrombin inhibitor, argatroban, in pediatric patients with HIT.

AB - Unfractionated heparin (UFH) is immunogenic, and heparin-dependent antibodies can be demonstrated 5 to 10 days postoperatively in 25% to 50% of adult postcardiac surgery patients. In a minority of these cases (1% to 3% if UFH is continued longer than 1 week) these antibodies strongly activate platelets, causing thrombocytopenia and massive thrombin generation (HIT syndrome). HIT is an intensely procoagulant disorder, and in adult cardiac surgery patients carries both significant thrombotic morbidity (38% to 81%) and mortality (28%). Despite the ubiquitous use of UFH in pediatric intensive care units, and the repeated and sustained exposures to UFH in neonates and young children with congenital heart disease, HIT has been infrequently recognized and reported in this patient population. However, emerging experience at our institution and elsewhere suggests that HIT is significantly under-recognized in pediatric congenital heart disease patients, and may in fact have an incidence and associated thrombotic morbidity and mortality in this patient group comparable to that seen in adult cardiac surgery patients. This article will review HIT in pediatric patients with congenital heart disease and emphasize the special challenges posed in clinical recognition, laboratory diagnosis, and treatment of HIT in this patient group. We will also outline our experience with the off-label use of the direct thrombin inhibitor, argatroban, in pediatric patients with HIT.

KW - Congenital heart disease

KW - Heparin-induced thrombocytopenia

KW - Pediatric cardiology

UR - http://www.scopus.com/inward/record.url?scp=2542502694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542502694&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 155

EP - 171

JO - Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual

JF - Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual

SN - 1092-9126

ER -